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1.  INTRODUCTION
Sex-related differences in lung cancer outcome have 
garnered a significant amount of interest recently 1. 
Sex-related differences in lung cancer pathology 
(women more often have adenocarcinoma, more 
women with lung cancers have K-ras mutations, and 
so on) 2,3, lung cancer risk factors (women appear to 
have an increased risk of cancer at lower levels of 
tobacco exposure) 4–6, natural history (women appear 
to have cancers with a slower doubling time) 5,7, and 
prognosis (women appear to have better survival with 
advanced disease) 8,9 have led to the examination 
of sex-specific factors that may be at work in lung 
cancer. Much work has focussed on hormones such 
as estrogen and progesterone 10,11 and their effect on 
lung cancer development and prognosis.
Recently, a study by Ganti et al. 12 suggested that 
the use of hormone replacement therapy [h r t  (ex-
ogenous estrogen)] is associated with significantly 
worse outcomes among women treated for non-
small-cell lung cancer (n s c l c ). Whether this finding 
was an effect of chance, confounders, a tumour-
related effect, or another cancer-related effect is 
unclear. Although estrogen replacement therapy has 
not shown a consistent effect on lung cancer inci-
dence (and may even be slightly protective 13), the 
possible association of estrogen replacement thera-
py with an aggressive course of lung cancer was 
highly interesting.
Various reasons for the association documented 
in the paper Ganti and colleagues can be speculated 
upon. In addition to statistical chance, these reasons 
include the effects of various confounders 14–16, effects 
of estrogen on tumour biology17–19, and effects of 
estrogen independent of tumour biology—for example, 
thrombosis risk20,21, among other possibilities.
ABSTRACT
Background
A recent report suggested that women who had been 
taking hormone replacement therapy (h r t ) experi-
enced significantly decreased survival after a lung 
cancer diagnosis. Given the large cohort of women 
who have received h r t , it is important to try to confirm 
that association.
Methods
We reviewed female patients diagnosed with lung 
cancer at our institution between January 1999 and 
December 2003 for age at diagnosis, disease stage, 
treatment, smoking history, h r t , performance status, 
weight loss, age at menopause, and overall survival. 
Patients were excluded if they had small-cell lung 
cancer or an unknown primary cancer, or if they had 
had previous or synchronous non-lung, non-skin can-
cers. Statistical analysis used the chi-square test for 
categorical variables and the Kaplan–Meier method 
and Cox regression model for univariate and multi-
variate analyses of overall survival.
Results
Of 397 eligible patients, most (68%) were stage iii 
or iv. The group included very few never-smokers 
(5%). The proportion of patients with experience of 
prior or current h r t  was 29%, and no effect on over-
all survival was observed. Median survival was 13 
months in the non-h r t  group and 14 months in the 
h r t  group. Significant factors predicting for overall 
survival included performance status, stage, and 
weight loss.
Conclusions
Stage, performance status, and weight loss are the 
most powerful predictors of survival for women with 
non-small-cell lung cancer. As compared with non-
h r t  users, patients with prior h r t  use did not have AYENI and ROBINSON
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Clearly, the importance of lung cancer as a leading 
cause of cancer-related death in women 22, coupled 
with the large magnitude of effect seen in the Ganti 
study, underscores the importance of trying to confirm 
the Ganti findings. Even though exogenous estrogen 
use has declined dramatically since data from the 
Women’s Health Initiative study were released, the 
issue is still very relevant 23.
2.  PATIENTS AND METHODS
The Hôpital Régional de Sudbury Regional Hospital 
(h r s r h ) Regional Cancer Program (r c p ) is a referral 
centre for patients with lung cancer in northeastern 
Ontario. Most incident cases of lung cancer in the 
region (>75%) are referred to the r c p  for either radia-
tion, systemic therapy, or follow-up of early-stage 
disease. The present study was approved by the 
research ethics board of the h r s r h .
Using h r s r h -r c p  records, we identified female 
patients who had been diagnosed with lung cancer 
between 1999 and 2003. Identified patients were 
excluded if they had small-cell lung cancer (s c l c ), 
carcinoid tumours, unknown primary tumours, or 
previous or synchronous non-lung, non-skin cancers 
and no pathology confirmation of lung cancer.
At their first clinic visit, all ambulatory patients 
had received a questionnaire asking for information 
about smoking history, weight loss, performance sta-
tus, comorbid illnesses, use of h r t  (current or former), 
previous surgeries, age at menarche and menopause, 
concurrent medications, and family history.
Information about stage, pathology, treatment, 
and outcome were extracted from the medical records, 
including pathology reports, radiology reports, and 
clinic notes. Information on h r t , smoking, and re-
lated factors was extracted from the nursing history 
and cross-referenced with the physician history. Use 
of h r t  included either current or previous use of ex-
ogenous estrogen as hormone replacement. Patients 
using exogenous estrogen for birth control purposes 
were not considered to have used h r t . Patients who 
were on tamoxifen or raloxifene were excluded. 
Current smoking status included patients currently 
smoking or having smoked in the preceding year; 
past smoking included any smoking of more than 2 
pack–years. For the survival analyses, cases in which 
death was not clearly documented were censored at 
the last known contact with patient.
The chi-square test was used for categorical 
variables, and Kaplan–Meier curves were generated 
for overall survival. Log-rank testing was used for 
survival analyses. The Cox regression model was 
also used for multivariate analyses.
3.  RESULTS
We identified 397 women that fit the n s c l c  patient cri-
teria and that had been diagnosed between 1999 and 
2003. Table i lists the characteristics of those patients. 
In addition, we examined 87 patients with s c l c .
Notably, only 5% of patients were never-smokers, 
this low proportion possibly being the result of the 
very high smoking rate in the population within the 
t a b l e  i  Baseline characteristics of the study patients 
Characteristic Value
Patients (n) 397
Stage (%)
i 24
ii 18
iii 26
iiv 42
Age group (%)
<60 years 31
60–75 years 50
>75 years 19
Median age (years) 66
Smoking status (%)
Never-smoker 5
Ex-smoker 22
Current smoker 71
e c o g  performance status (%)
0–1 56
2 22
3–4 21
Weight loss (%)
<5% 48
5%–10% 15
>10% 29
Histology (%)
Adenocarcinoma 41
Squamous cell 40
Large cell 5
n s c l c  (not defined) 12
Bronchioalveolar 2
Hormone replacement (%)
Yes 29
No 58
Unknown 11
Premenopausal 2
Initial treatment at diagnosis (%)
Surgery alone 15
Surgery and adjuvant chemotherapy 2
Chemotherapy alone 32
Radiation alone 28
No treatment 10
Combined modality (chemorads) 10
Surgery and adjuvant radiation 2 
e c o g  = Eastern Cooperative Oncology Group; n s c l c  = non-small-
cell lung cancer; chemorads = chemotherapy plus radiation.HRT, AGE, AND OUTCOMES FOR WOMEN WITH NSCLC
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catchment area for the h r s r h  24. This proportion is also 
consistent with previously published research from 
the area, which shows a more than 95% smoking rate 
for lung cancer patients in northern Ontario24.
Use of h r t  was documented in 29% of the pa-
tients, no h r t  use in 58%, and unknown use in 11%. 
The remaining 2% of the patients were known to 
be premenopausal. The patients with unknown h r t  
use were principally those who were not seen in 
the ambulatory clinic, but as inpatients for radia-
tion (that is, for brain metastases or with very poor 
performance status), and who thus did not complete 
a questionnaire.
Figure 1 shows the overall survival for women 
with n s c l c  based on whether they had or had not 
received h r t . No effect of h r t  on overall survival 
was observed, median survivals being 14 months for 
h r t  recipients and 13 months for h r t  non-recipients 
(log-rank p = 0.6). The 2-year survival was also vir-
tually identical, with 32% of patients in the h r t  arm 
and 30% of patients in the non-h r t  arm being alive 
at 2 years. When a multivariate analysis using stage, 
age, treatment type, performance status, weight loss, 
and use of hormone therapy was analyzed using the 
Cox regression model, there was still no significant 
association with h r t  use (p = 0.7). In addition, given 
that multiple confounding treatment-related factors 
may have been insufficiently addressed using these 
models, exploratory analyses for specific subgroups 
of patients were attempted—for example, just patients 
with stage iv disease or with surgically treated stage i 
and ii disease. In neither of those groups was any 
significant trend observed. Patients with s c l c  were 
analyzed separately, and no significant difference was 
seen [hazard ratio (h r ): 0.8 for h r t  users versus non-
users; median survival: 8 months for both groups].
In contrast, Figure 2 shows the association of 
survival with the known prognostic factors for lung 
cancer—most notably, stage, performance status, 
and weight loss (p < 0.01 for all comparisons). In 
multivariate analyses, stage and performance status 
retained their significance (both with p < 0.02), but 
weight loss did not (p = 0.1). In multivariate analyses 
using stage, age, weight loss, initial treatment, and 
performance status, h r t  use was not associated with 
inferior outcomes (h r : 0.8; p = nonsignificant).
Looking at subgroups, the cohort included too few 
never-smokers (only 5% of total) to do an adequately 
powered subset analysis. We observed no association 
with estrogen replacement and survival in any sub-
group based on stage, initial therapy, age, or tumour 
histology. Other markers of estrogen exposure, such 
as age of menarche and menopause, were not evalu-
ated. Prior hysterectomy was documented for roughly 
30% of the patients, making an accurate estimation 
of age at menopause difficult.
4.  DISCUSSION
The previously published association between h r t  use 
and adverse lung cancer outcomes was not confirmed 
using this independent data set. Commonly accepted 
prognostic factors for lung cancer in general—notably 
performance status and stage, maintained their ro-
bust association with overall survival in the women 
studied 24,25.
Several factors may explain the lack of associa-
tion seen in our study as compared with the study by 
Ganti et al. Limitations in both studies include a lack 
of information on the total duration of h r t  use, the 
indications for h r t , and whether h r t  use continued 
after diagnosis. For instance, in the later period, the 
use of combined h r t  was widely known to signifi-
cantly increase thrombosis risk 26, and it is probable 
that h r t  would have been stopped after a diagnosis 
of lung cancer for this reason. In contrast, the com-
mentary for the Ganti study made the assumption 
that women using h r t  who were diagnosed with lung 
cancer would continue their h r t  use after diagnosis. It 
is possible that some of these unmeasured variables 
affected the conclusions.
A second important difference is that our study 
did not initially include patients with histologies other 
than n s c l c . Although this was a difference in the 
studies, it is extremely unlikely that the differences 
in outcome can be attributed solely to this difference 
in methodology. Approximately 24% of patients in 
the study by Ganti et al. had s c l c . Given that s c l c  
and n s c l c  behave differently and that much of the 
previous work on the association between estrogen 
and lung cancer has been in the n s c l c  population, we 
elected to include only patients with n s c l c  histology 
in our primary analysis. However, even when the s c l c  
population was looked at separately, no clear effect 
was observed.
f i g u r e  1  Overall survival as a function of hormone replacement 
therapy (h r t ) use. Users of h r t  had a median survival of 14 months 
as compared with 13 months for non-users of h r t .AYENI and ROBINSON
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A third, and probably the most important, differ-
ence between the studies is the dramatic difference in 
overall survival. In our study, 5-year survival was in 
only the 20% range for both h r t  and non-h r t  users. On 
the other hand, median survival in the Ganti study for 
the non-h r t  users was more than 6 years, and median 
survival for the h r t  users (18% of the total) was more 
than 3 years. The survival differences between that 
study and ours are significant, suggesting that these 
two populations were different, either because of 
referral bias or practice difference. Even a 39-month 
median survival for an unselected lung cancer 
population is impressive when compared with U.S. 
Surveillance, Epidemiology, and End Results (s e e r) 
database data showing a 5-year survival of roughly 
15% for women with lung cancer in 1995 27. In fact, 
in looking at the 47% of patients in the Ganti study 
who had stage iii or iv disease, even the 39-month 
median survival for h r t  users is rather impressive. 
The survival data from our centre are consistent with 
survival data from across Ontario in lung cancer 28 and 
closer to the expected survival rates for women with 
lung cancer documented in the s e e r database 27.
Thus, although it is possible that h r t  and estrogen 
play a role in the survival of women with lung cancer, 
the degree of difference seen in the paper by Ganti et 
al. was certainly not duplicated in our study. This dif-
ference may be the result of a select group of patients 
with an extremely good prognosis, but in general, 
other factors such as stage and performance status 
significantly outweigh h r t  as a prognostic factor.
Clearly, the present study has all the limitations of 
a retrospective methodology, as did the Ganti study. No 
firm conclusions can be drawn regarding the role of h r t  
on lung cancer survival in women. Further evaluation 
concerning the role of estrogen and other hormones in 
the development, progression, and treatment of lung 
cancer in women is indicated. Information on estrogen 
interactions with MDM2 single-nucleotide polymor-
phisms may be particularly intriguing. However, the 
present study does not support the notion that current 
or prior use of h r t  is, in itself, an adverse prognostic 
feature of significance in n s c l c .
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